SCHEMBL17465396

SCHEMBL17465396

O=C(Nc1ncnc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3F)csc12)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ LGALS9 O00182 1/20 0.38
▸ LGALS1 P09382 1/20 0.38
▸ LGALS3 P17931 1/20 0.38
▸ LGALS7; LGALS7B P47929 1/20 0.38
▸ HK1 P19367 1/20 0.37
▸ HK2 P52789 1/20 0.37
▸ ADORA1 P30542 7/20 0.37
▸ ADORA3 P0DMS8 3/20 0.37
▸ ADORA2A P29274 3/20 0.37
▸ ADORA2B P29275 2/20 0.37
▸ BRD4 O60885 1/20 0.35
▸ PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479346 1.00 LGALS9 (0.38) LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1
SCHEMBL17465435 0.92 BRD4 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL17465407 0.92 PDPK1 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL17465432 0.90 BRD4 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL17465397 0.84 SMN1; SMN2 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL21837294 0.84 PRMT6 (0.33) ADORA1BRD4PDPK1
SCHEMBL21837296 0.82 TYMP (0.42) ADORA1ADORA3ADORA2ABRD4
SCHEMBL19644596 0.81 BRD4 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL17465401 0.79 BRD4 (0.35) ADORA1ADORA3ADORA2ABRD4PDPK1
SCHEMBL17465394 0.79 PDPK1 (0.39) ADORA1ADORA3ADORA2ABRD4PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4023650-A1 4'-SUBSTITUTED-FURO[3,2-D]PYRIMIDINE AND -PYRROLO[3,2- D]PYRIMIDINE DERIVATIVES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2022-07-06 — — EP disclosed
EP-3693367-B1 THIENO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES INC (US) 2022-02-16 — — EP disclosed
EP-3174870-B1 THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES INC (US) 2020-04-15 — — EP disclosed
US-20180072755-A1 THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2018-03-15 — — US disclosed
US-9828388-B2 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2017-11-28 — — US disclosed
US-9828388-B2 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2017-11-28 — — US disclosed
EP-3174870-A1 THIENO [3,2-D]PYRIMIDINE, FURO [3,2,D]PYRIMIDINE, AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2017-06-07 — — EP disclosed
WO-2016018697-A1 THIENO [3,2-D] PYRIMIDINE, FURO [3,2,D] PYRIMIDINE, AND PYRROLO [3,2-D] PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. (US) 2016-02-04 — — WO disclosed
WO-2016018697-A1 THIENO [3,2-D] PYRIMIDINE, FURO [3,2,D] PYRIMIDINE, AND PYRROLO [3,2-D] PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. (US) 2016-02-04 — — WO disclosed
US-20160024107-A1 THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-01-28 — — US disclosed
US-20160024107-A1 THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024107-A1 THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS DPYD, TYMS, TYMP LGALS9 3916/4885LGALS1 4483/4885LGALS3 4189/4885
US-20180072755-A1 THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS DPYD, TYMS, TYMP LGALS9 3916/4885LGALS1 4483/4885LGALS3 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback